Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Hemo Malignancies
Hematology
| Question | Answer |
|---|---|
| Pathophysiologic Basis for Myeloproliferative Disorders | Acquired clonal abnormalities of the hematopoietic stem cell; May see changes in all stem cell lines (erythroid, myeloid, & pt cells); poss specific chromosomal changes |
| True increase in RBC mass | Primary P. vera |
| Relative increase in RBC mass | Secondary P. vera |
| Conditions causing secondary P. vera | Hypoxia (COPD, heart disease, smoking), renal disease, ACS, dehydration, high altitude, blood doping |
| P. vera: incidence/prevalence | 60 to 70 yrs (mean age at dx: 65 yrs; rare in pt <40); M/F = 1.2 to 1 |
| P. vera S/S | Problems related to hyperviscocity & hypervolemia; pruritis (esp after hot showers/baths), thromboses, dyspnea, HA, visual disturbance, tinnitus; LUQ pain, easy bleeding |
| Hallmark of P. vera = | Erythrocytosis |
| P. vera H & H | M: >18.5 ; F: >16.5 (often HCT is > 60%) |
| P. vera mgmt | Therapeutic phlebotomy (goal Hct <45 % M, <43% F). Myelosuppression PRN. Hydroxyurea (watch WBC/PLT). Anagrelide if thrombocytosis. Aspirin 81mg. Antihistamine for pruritis. Allopurinol PRN. |
| P. vera survival prognosis | Median if treated: 11-15 year; untreated = 18 months. |
| Causes of Reactive (Secondary) Thrombocytosis | Severe hemorrhage; splenectomy; neoplasms; chronic inflame dz; post acute infxn; B12 def; meds (vincristine, epi); ETOH |
| Causes of Reactive (Secondary) Thrombocytosis | Severe hemorrhage; splenectomy; neoplasms; chronic inflame dz; post acute infxn; B12 def; meds (vincristine, epi); ETOH |
| Thrombocytosis S/S | Median 50-60 yrs (but all ages); rare in kids; slight female predominance; 1/3 of pts asymptomatic at dx; 2/3 of pts vasomotor s/s (HA, dizziness, visual changes) or complications from thrombosis/bleeding |
| Thrombocytosis findings | Splenomegaly (>25% ); hepatomegaly (20%); leukocytosis, erythrocytosis, mild anemia; occ immature precursor cells and/or large plts; BM bx: increased number of megakaryocytes, else normal |
| Thrombocytosis Mgmt | ASA to prevent thrombosis; Cytoreductive tx (hydroxyurea, anagrelide); Plt pheresis if severe bleed; BM bx for Philadelphia chr. |
| Thrombocytosis Prognosis | 10 y survival = 64-80% ; 1-5% evolve into AML, 10-15% evolve into myelofibrosis |
| Disorder in which bone marrow is replaced with scar tissue, leading to anemia | Myelofibrosis |
| Myelofibrosis findings | Fibrosis on BM; splenomegaly; giant plts; teardrop poikilocytosis |
| Myelofibrosis peak incidence & survival | 50-70 yrs old; median survival is 2-5 yr from onset; occurs in 10 to 30% of pts w/P. vera |
| Cause of Myelofibrosis | Unknown |
| Increased bone marrow production of megakaryocytes leads to increased peripheral platelet count | Myelofibrosis |
| Myelofibrosis S/S | Early: asymptomatic; later: malaise; wt loss; splenomegaly/splenic infarction; hepatomegaly in 50% of pts |
| Myelofibrosis findings | BM aspirate = dry tap; anemia generally increases over time; normochromic-normocytic & mild poik; NRBCs |
| Myelofibrosis mgmt | No tx to reverse/ctrl underlying pathology; tx supportive; mgmt of complications; (Procrit, Aranesp); pRBC & plt txn; Thalidomide & Revlimid? ; allogeneic BM txplt for younger pt? ; Median survival 5 yrs |
| Acquired clonal disorders of the hematopoietic stem cell | MDS |
| ______ cytopenias affect one or more cell lines (RBC, WBC, and/or PLTs) | MDS |
| Dz occurs when blood cells do not develop into mature cells, but rather stay in an immature stage within the BM | MDS |
| Some chromosomal abnormalities (5q – loss of part of the long arm of chromosome 5); “pre-leukemia” | MDS |
| MDS: risk factors include exposure to: | Benzene, radiation, chemotx agents (esp alkylating agents & anthracyclines) |
| MDS pts | Average age ≥ 60 years; pts often asymptomatic; If S/S: fatigue, bleeding, recurrent infxn, fever, splenomegaly, pallor |
| MDS Labs | 85% of pts anemic; 50% neutropenia; 30% thrombocytopenia |
| MDS CBC | Normal or low RBC, WBC, PLTS; Blasts in BM <20%; Pelger-Huet cells (bi-lobed neutrophils) |
| MDS: >20% blasts in BM indicates: | Transition into acute leukemia |
| Blasts in BM <20%; Pelger-Huet cells (bi-lobed neutrophils) seen in: | MDS |
| MDS BM shows: | Hypercellular marrow with delayed/abnormal maturation ( 5q- chromosomal abnormality, ring sideroblasts) |
| MDS Mgmt | Monitor closely (lest transformation); Cytokine and transfusion support; chemotherapy (Thalidomide, Lenolidimide for 5q- syndrome, Azacitadine); Allogeneic BM txplt only curative therapy (most pts too old) |
| MDS: Allogeneic BM txplt may cure ?? % of pts | 30-50%, for pts <60 y.o. |
| Cornerstone for tx of MDS | Supportive care |
| MDS prognosis | Ultimately fatal disease; Infections or bleeding common causes of death |
| Risk of transformation to leukemia depends on: | Percentage of blasts in BM |
| Etiology of multiple myeloma | Etiology unknown. May be associated with pesticides, paper production, leather tanning, exposure to radiation from nukes |
| Replacement of normal bone marrow by plasma cells leads to bone marrow failure | Multiple myeloma |
| Lytic lesions predisposing patients to bone pain, pathologic fractures, and hypercalcemia | Multiple myeloma |
| Multiple myeloma S/S | Fatigue/Anemia; Bone pain (from lytic lesions: back and ribs); Recurrent infxn; Sp cord compression; Unexplained fractures; Kidney failure; Hyperviscosity syndrome |
| Multiple myeloma findings | Anemia; Rouleaux; M-spike on SPEP; Bence-Jones proteins in Urine; Hypercalcemia from bony dz; Renal failure from light chain excretion |
| Multiple myeloma classic triad: | Plasmacytosis (BM bx w/plasma cells > 5%); Bone lytic lesions (on bone survey ); M-protein in serum and/or urine |
| Important to differentiate btw multiple myeloma and: | MGUS (monoclonal gammopathy of unknown significance) |
| Thalidomide may be part of tx for: | Myelofibrosis, MDS, multiple myeloma |
| Multiple myeloma mgmt | Chemo; Local radiation (pain ctrl); Autologous BMT / SCT for LT survival (mortality rate of 40-50%); hypercalcemia tx (bisphosphonates) |
| Multiple myeloma Prognosis: | Median survival w/ transplant = 7 yrs; Median survival with chemo: 3 yrs |
| MGUS prevalence | Present in 1% all adults, 3% over 70yr; Progresses to multiple myeloma 25% of cases |
| What MGUS looks like | Usually, pts have monoclonal IgG spike <2.5g/dL, M-spike remains stable |
| Malignancy of B lymphocytes | Waldenstrom’s Macroglobulinemia |
| Waldenstrom Macroglobulinemia causes overproduction of: | Monoclonal macroglobulin (IgM antibody) |
| Waldenstrom Sx/Sx | Fatigue; hyperviscosity syndrome (nausea, vertigo, visual disturbances, mucosal or GI bleeding); wt loss, HA, cold hypersensitivity, peripheral neuropathy, hepatomegaly, splenomegaly, engorged retinal veins |
| Fatigue, cold hypersensitivity, peripheral neuropathy, engorged retinal veins may indicate: | Waldenstrom Macroglobulinemia |
| Hallmark of Waldenstrom: | Monoclonal IgM spike in SPEP |
| Waldenstrom Macroglobulinemia Findings | Anemia ; Plasmacytic lymphocytes on BM bx; Serum viscosity 1.4 to 1.8 x that of water; Bone radiographs normal |
| Waldenstrom is differentiated from MGUS by: | Presence of bone marrow infiltration |
| Waldenstrom Macroglobulinemia mgmt | If asymptomatic, follow expectantly; Plasmapheresis for hyperviscosity syndrome; Fludarabine & Rituximab prefered to alkylating agent tx; BM txpt? ; Median survival 3-5 yrs |
| Oncologic emergencies | Febrile Neutropenia; SVC Syndrome (superior vena cava syndrome); Tumor Lysis Syndrome; Hypercalcemia; Cord compression (myelomas) |
| Only curative tx for MDS | Allogeneic BMT |
| Type of HL that accounts for 80% of HL cases | Nodular sclerosing HL |
| Giant plts & teardrop poik | Myelofibrosis |
| Lytic lesions | multi myeloma |
| Serum viscosity 1.4-1.8 xH2O visc | Waldenstrom’s |
| Preleukemia | MDS |
| Immunoproferative diseases | Waldenström; Multiple Myeloma; MGUS |
| Anagrelide may be used for: | P vera; thrombocytosis |
| Cytoreductive therapies include: | Anagrelide, hydroxyurea |
| Post-showering pruritis, plethora, dyspnea, HA, visual disturbance, tinnitus, HTN, splenomegaly, engorged retinal veins, thromboses, high H&H | Polycythemia vera |
| 5-20% of P vera cases evolve into this over 20 years | myelofibrosis or acute leukemia |
| "Spent phase" in P vera = | 15% of P vera patients: HSM, anemia, circulating immature WBCs, high WBC. BM: myelofibrosis. Tx supportive. Median survival 2 years. May -> to AML. |
| 3 big causes of secondary erythrocytosis | 1 Reactive 2/2 hypoxia (altitude, pulmo dz, smoking, cyanotic heart dz). 2 Pathologic (renal cell ca, renal dz, uterine fibroid, hepatoma, cerebellar hemangioma, high androgen levels). 3 Relative 2/2 decreased plasma volume (diuretics) |
| Hemochromatosis mgmt | Phlebotomy (goal mild anemia, low ferritin, transferring saturation <30%). +/- chelating agents (dereroxamine IM). Avoid alcohol or vitamin C. |
Created by:
Abarnard
Popular Medical sets